Last reviewed · How we verify
butyrate enemas + routine management
Butyrate enemas deliver short-chain fatty acids directly to the colon to reduce inflammation and promote healing of the intestinal mucosa.
Butyrate enemas deliver short-chain fatty acids directly to the colon to reduce inflammation and promote healing of the intestinal mucosa. Used for Ulcerative colitis (adjunctive therapy with routine management).
At a glance
| Generic name | butyrate enemas + routine management |
|---|---|
| Sponsor | Assistance Publique Hopitaux De Marseille |
| Drug class | Short-chain fatty acid |
| Target | GPR43 and GPR109A (butyrate receptors) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Inflammatory Bowel Disease |
| Phase | Phase 3 |
Mechanism of action
Butyrate is a short-chain fatty acid that serves as a primary fuel source for colonocytes and enhances intestinal barrier function. It reduces inflammatory cytokine production, increases tight junction proteins, and promotes the growth of beneficial commensal bacteria. When administered as an enema in combination with standard medical management, it aims to improve mucosal healing and reduce disease activity in inflammatory bowel conditions.
Approved indications
- Ulcerative colitis (adjunctive therapy with routine management)
Common side effects
- Abdominal discomfort
- Rectal irritation
- Diarrhea
Key clinical trials
- Effects of Butyrate Enemas on Postoperative Intestinal Mobility Disorders in Hirschsprung's Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: